General Information of Drug (ID: DMXZ9T3)

Drug Name
AC-170
Synonyms
88139-91-7; 5-Bromo-2-hydroxymethylpyridine; (5-Bromopyridin-2-yl)methanol; 2-hydroxymethyl-5-bromopyridine; 5-Bromo-2-(hydroxymethyl)pyridine; (5-bromopyrid-2-yl)methanol; 5-Bromo-2-pyridinemethanol; (5-Bromo-pyridin-2-yl)-methanol; 2-PYRIDINEMETHANOL, 5-BROMO-; 5-BROMOPYRIDINE-2-METHANOL; (5-bromo-2-pyridyl)methanol; (5-bromo-2-pyridyl)methan-1-ol; AC-170; (5-Bromo-pyridin-2-yl)methanol (5-Bromo-2-hydroxymethylpyridine); zlchem 391; PubChem7710; PubChem12387; ACMC-209qrb; AC1NP90H; 5-bromo-2-pyridine methanol; KSC494K9D
Indication
Disease Entry ICD 11 Status REF
Allergic conjunctivitis 9A60.02 Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 188.02
Logarithm of the Partition Coefficient (xlogp) 0.7
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C6H6BrNO
IUPAC Name
(5-bromopyridin-2-yl)methanol
Canonical SMILES
C1=CC(=NC=C1Br)CO
InChI
InChI=1S/C6H6BrNO/c7-5-1-2-6(4-9)8-3-5/h1-3,9H,4H2
InChIKey
RUCZFWMEACWFER-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5200169
CAS Number
88139-91-7
TTD ID
D01JFM

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic conjunctivitis
ICD Disease Classification 9A60.02
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02132169) A Multi-Center Study Evaluating the Safety of AC-170 0.24%. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of NicOx SA.